Vernal Keratoconjunctivitis Market Report and Forecast 2025-2034
Description
The vernal keratoconjunctivitis market was valued at USD 463.55 Million in 2024, driven by advances in treatment options across the 8 major markets. The market is anticipated to grow at a CAGR of 6.10% during the forecast period of 2025-2034, with the values likely to reach USD 838.01 Million by 2034.
Vernal Keratoconjunctivitis Market Overview
Vernal keratoconjunctivitis is a long-lasting allergic condition triggered by sensitivity to allergens found in the air. Younger males are the ones that are more commonly affected, showing symptoms like itching, sensitivity to light, redness, and discharge of mucus. The rise in vernal keratoconjunctivitis cases, especially in adults, is driving the market growth. Additionally, there is a growing preference for using immunomodulatory therapies, which are poised to impact the market dynamics in the forecast period.
Vernal Keratoconjunctivitis Market Growth Drivers
Increasing Recognition of Vernal Keratoconjunctivitis Cases in Adults to Drive Market Growth
The market for vernal keratoconjunctivitis is expanding as more adult cases are identified. A United States-based study demonstrated that approximately 10% of cases persist into adulthood or arise post-puberty, broadening the patient population and necessitating new treatments to address issues, thereby stimulating market expansion.
Vernal Keratoconjunctivitis Market Trends
The market is witnessing several trends and developments to improve the current scenario. Some of the notable trends are as follows:
Increasing Acquisition Events
The acquisition trend, such as Harrow acquiring Santen’s ophthalmic portfolio that includes VERKAZIA®, shows market consolidation. Major companies are enhancing their portfolios to offer all-inclusive solutions for eye care, which is set to positively influence market growth.
Shift Toward Immunomodulatory Therapies
Immunomodulatory therapies, like Cyclosporine A, are trending in the market for treating vernal keratoconjunctivitis. This shift focuses on addressing immune mechanisms rather than just symptoms, in line with a broader move towards safer, more targeted therapies.
Advances in Treatment Options
The introduction of specialized treatments such as Verkazia® by Santen Pharmaceutical Co., Ltd., a Japanese pharmaceutical company, for patients suffering from vernal keratoconjunctivitis is a major driver of growth, meeting medical needs and increasing opportunities for innovation in the market.
Growth in Allergy and Immunology Clinics
A significant market trend is the expansion of specialty clinics in allergology and immunology, which is improving access to medical care for vernal keratoconjunctivitis patients, especially in regions with higher prevalence. Such clinics offer targeted treatments that have the potential to reduce the progression of symptoms more effectively and are anticipated to accommodate the growing market demand for advanced vernal keratoconjunctivitis therapies.
Vernal Keratoconjunctivitis Market Segmentation
The market report offers a detailed analysis of the market based on the following segments:
Market Breakup by Treatment:
Segmentation Based on Treatment to Witness Substantial Growth
Based on the treatment, the market is segmented into nonsteroidal anti-inflammatory drugs – NSAIDs, mast cell stabilizers, antihistamines, topical corticosteroids, cyclosporine, and others. Topical corticosteroids are expected to dominate the market share as they remain the most widely used option due to their effectiveness in rapidly reducing inflammation and alleviating symptoms like itching, pain, and sensitivity to light.
Vernal Keratoconjunctivitis Market Analysis by Region
Based on region, the market report covers the United States, EU-4 (Germany, France, Italy, Spain), United Kingdom, Japan, and India. The United States is one of the leading markets owing to the high prevalence of conjunctivitis, coupled with an increased demand for effective treatments. With improved healthcare services and accessibility, the United States market for vernal keratoconjunctivitis is projected to witness significant growth in the coming years.
Leading Players in the Vernal Keratoconjunctivitis Market
The key features of the market report comprise patent analysis, clinical trial analysis, grants analysis, funding and investment analysis, and strategic initiatives by the leading players. The major companies in the market are as follows:
Santen Pharmaceutical Co., Ltd.
Santen Pharmaceutical, is a Japanese company specialized specializing in ophthalmology, was granted FDA authorization in June 2021, for Verkazia, an eye drop medication containing cyclosporine, to manage vernal keratoconjunctivitis.
Novartis Pharmaceuticals Corporation
Novartis is a cutting-edge pharmaceutical company that introduced ALOMIDE eye drops for managing vernal keratoconjunctivitis, stopping allergic responses by inhibiting mast cells from releasing inflammatory substances.
Senju Pharmaceutical Co., Ltd.
Senju Pharmaceutical Co., Ltd., headquartered in Japan, has a prominent presence in the market. The company specializes in ophthalmology, boasting a robust portfolio of medications for managing allergic conjunctivitis and vernal keratoconjunctivitis.
Other key players in the market include Akari Therapeutics Plc., Allakos Inc., Satellos Bioscience Inc., Viatris Inc., Aldeyra Therapeutics, Inc., Laboratoires Thea S.A.S., and Astellas Pharma Inc.
Key Questions Answered in the Vernal Keratoconjunctivitis Market
Vernal Keratoconjunctivitis Market Overview
Vernal keratoconjunctivitis is a long-lasting allergic condition triggered by sensitivity to allergens found in the air. Younger males are the ones that are more commonly affected, showing symptoms like itching, sensitivity to light, redness, and discharge of mucus. The rise in vernal keratoconjunctivitis cases, especially in adults, is driving the market growth. Additionally, there is a growing preference for using immunomodulatory therapies, which are poised to impact the market dynamics in the forecast period.
Vernal Keratoconjunctivitis Market Growth Drivers
Increasing Recognition of Vernal Keratoconjunctivitis Cases in Adults to Drive Market Growth
The market for vernal keratoconjunctivitis is expanding as more adult cases are identified. A United States-based study demonstrated that approximately 10% of cases persist into adulthood or arise post-puberty, broadening the patient population and necessitating new treatments to address issues, thereby stimulating market expansion.
Vernal Keratoconjunctivitis Market Trends
The market is witnessing several trends and developments to improve the current scenario. Some of the notable trends are as follows:
Increasing Acquisition Events
The acquisition trend, such as Harrow acquiring Santen’s ophthalmic portfolio that includes VERKAZIA®, shows market consolidation. Major companies are enhancing their portfolios to offer all-inclusive solutions for eye care, which is set to positively influence market growth.
Shift Toward Immunomodulatory Therapies
Immunomodulatory therapies, like Cyclosporine A, are trending in the market for treating vernal keratoconjunctivitis. This shift focuses on addressing immune mechanisms rather than just symptoms, in line with a broader move towards safer, more targeted therapies.
Advances in Treatment Options
The introduction of specialized treatments such as Verkazia® by Santen Pharmaceutical Co., Ltd., a Japanese pharmaceutical company, for patients suffering from vernal keratoconjunctivitis is a major driver of growth, meeting medical needs and increasing opportunities for innovation in the market.
Growth in Allergy and Immunology Clinics
A significant market trend is the expansion of specialty clinics in allergology and immunology, which is improving access to medical care for vernal keratoconjunctivitis patients, especially in regions with higher prevalence. Such clinics offer targeted treatments that have the potential to reduce the progression of symptoms more effectively and are anticipated to accommodate the growing market demand for advanced vernal keratoconjunctivitis therapies.
Vernal Keratoconjunctivitis Market Segmentation
The market report offers a detailed analysis of the market based on the following segments:
Market Breakup by Treatment:
- Nonsteroidal Anti-inflammatory Drugs - NSAIDs
- Mast Cell Stabilizers
- Antihistamines
- Topical Corticosteroids
- Cyclosporine
- Others
- Ointment
- Gel
- Tablets
- Others
- Hospitals and Clinics
- Online Pharmacies
- Retail Pharmacies
- Others
- United States
- EU-4 and the United Kingdom
- Germany
- France
- Italy
- Spain
- United Kingdom
- Japan
- India
Segmentation Based on Treatment to Witness Substantial Growth
Based on the treatment, the market is segmented into nonsteroidal anti-inflammatory drugs – NSAIDs, mast cell stabilizers, antihistamines, topical corticosteroids, cyclosporine, and others. Topical corticosteroids are expected to dominate the market share as they remain the most widely used option due to their effectiveness in rapidly reducing inflammation and alleviating symptoms like itching, pain, and sensitivity to light.
Vernal Keratoconjunctivitis Market Analysis by Region
Based on region, the market report covers the United States, EU-4 (Germany, France, Italy, Spain), United Kingdom, Japan, and India. The United States is one of the leading markets owing to the high prevalence of conjunctivitis, coupled with an increased demand for effective treatments. With improved healthcare services and accessibility, the United States market for vernal keratoconjunctivitis is projected to witness significant growth in the coming years.
Leading Players in the Vernal Keratoconjunctivitis Market
The key features of the market report comprise patent analysis, clinical trial analysis, grants analysis, funding and investment analysis, and strategic initiatives by the leading players. The major companies in the market are as follows:
Santen Pharmaceutical Co., Ltd.
Santen Pharmaceutical, is a Japanese company specialized specializing in ophthalmology, was granted FDA authorization in June 2021, for Verkazia, an eye drop medication containing cyclosporine, to manage vernal keratoconjunctivitis.
Novartis Pharmaceuticals Corporation
Novartis is a cutting-edge pharmaceutical company that introduced ALOMIDE eye drops for managing vernal keratoconjunctivitis, stopping allergic responses by inhibiting mast cells from releasing inflammatory substances.
Senju Pharmaceutical Co., Ltd.
Senju Pharmaceutical Co., Ltd., headquartered in Japan, has a prominent presence in the market. The company specializes in ophthalmology, boasting a robust portfolio of medications for managing allergic conjunctivitis and vernal keratoconjunctivitis.
Other key players in the market include Akari Therapeutics Plc., Allakos Inc., Satellos Bioscience Inc., Viatris Inc., Aldeyra Therapeutics, Inc., Laboratoires Thea S.A.S., and Astellas Pharma Inc.
Key Questions Answered in the Vernal Keratoconjunctivitis Market
- What was the vernal keratoconjunctivitis market value in 2024?
- What is the vernal keratoconjunctivitis market forecast outlook for 2025-2034?
- What are the regional markets covered in the EMR report?
- What is the market segmentation based on the treatment?
- What is the market breakup based on the dosage form?
- What is the market breakup based on the distribution channel?
- What are the major factors aiding the vernal keratoconjunctivitis market demand?
- How has the market performed so far and how is it anticipated to perform in the coming years?
- What are the major drivers, opportunities, and restraints in the market?
- What are the major trends influencing the market?
- Which regional market is expected to dominate the market share in the forecast period?
- Which country is likely to experience elevated growth during the forecast period?
- Who are the key players involved in the vernal keratoconjunctivitis market?
- What is the patent landscape of the market?
- What are the current unmet needs and challenges in the market?
- How are partnerships, collaborations, mergers, and acquisitions among the key market players shaping the market dynamics?
Table of Contents
400 Pages
- 1 Preface
- 1.1 Objectives of the Study
- 1.2 Key Assumptions
- 1.3 Report Coverage – Key Segmentation and Scope
- 1.4 Research Methodology
- 2 Executive Summary
- 3 Vernal Keratoconjunctivitis Market Overview – 8 Major Markets
- 3.1 Vernal Keratoconjunctivitis Market Historical Value 2018-2024
- 3.2 Vernal Keratoconjunctivitis Market Forecast Value 2025-2034
- 4 Vendor Positioning Analysis
- 4.1 Key Vendors
- 4.2 Prospective Leaders
- 4.3 Niche Leaders
- 4.4 Disruptors
- 5 Vernal Keratoconjunctivitis Overview
- 5.1 Guidelines and Stages
- 5.2 Pathophysiology
- 5.3 Screening and Diagnosis
- 5.4 Treatment Pathway
- 6 Patient Profile
- 6.1 Patient Profile Overview
- 6.2 Patient Psychology and Emotional Impact Factors
- 6.3 Risk Assessment and Treatment Success Rate
- 7 Vernal Keratoconjunctivitis Market - Epidemiology Scenario and Forecast – 8 Major Markets
- 7.1 8MM Epidemiology Scenario Overview 2018-2034
- 7.2 Prevalence, by Country
- 7.2.1 United States
- 7.2.2 United Kingdom
- 7.2.3 EU4
- 7.2.4 India
- 7.2.5 Japan
- 7.3 Diagnosed Cases, by Country
- 7.3.1 United States
- 7.3.2 United Kingdom
- 7.3.3 EU4
- 7.3.4 India
- 7.3.5 Japan
- 7.4 Treatment Seeking Rate, by Country
- 7.4.1 United States
- 7.4.2 United Kingdom
- 7.4.3 EU4
- 7.4.4 India
- 7.4.5 Japan
- 8 Vernal Keratoconjunctivitis Market Landscape – 8 Major Markets
- 8.1 Vernal Keratoconjunctivitis Market: Developers Landscape
- 8.1.1 Analysis by Year of Establishment
- 8.1.2 Analysis by Company Size
- 8.1.3 Analysis by Region
- 8.2 Vernal Keratoconjunctivitis Market: Product Landscape
- 8.2.1 Analysis by Treatment
- 8.2.2 Analysis by Dosage Form
- 9 Vernal Keratoconjunctivitis Market Challenges and Unmet Needs
- 9.1 Treatment Pathway Challenges
- 9.2 Compliance and Drop-Out Analysis
- 9.3 Awareness and Prevention Gaps
- 10 Cost of Treatment
- 11 Vernal Keratoconjunctivitis Market Dynamics
- 11.1 Market Drivers and Constraints
- 11.2 SWOT Analysis
- 11.2.1 Strengths
- 11.2.2 Weaknesses
- 11.2.3 Opportunities
- 11.2.4 Threats
- 11.3 PESTEL Analysis
- 11.3.1 Political
- 11.3.2 Economic
- 11.3.3 Social
- 11.3.4 Technological
- 11.3.5 Legal
- 11.3.6 Environment
- 11.4 Porter’s Five Forces Model
- 11.4.1 Bargaining Power of Suppliers
- 11.4.2 Bargaining Power of Buyers
- 11.4.3 Threat of New Entrants
- 11.4.4 Threat of Substitutes
- 11.4.5 Degree of Rivalry
- 11.5 Key Demand Indicators
- 11.6 Key Price Indicators
- 11.7 Industry Events, Initiatives, and Trends
- 11.8 Value Chain Analysis
- 12 Vernal Keratoconjunctivitis Market Segmentation 218-2034 - 8 Major Markets
- 12.1 Vernal Keratoconjunctivitis Market 2018-2034 by Treatment
- 12.1.1 Market Overview
- 12.1.2 Nonsteroidal Anti-inflammatory Drugs - NSAIDs
- 12.1.3 Mast Cell Stabilizers
- 12.1.4 Antihistamines
- 12.1.5 Topical Corticosteroids
- 12.1.6 Cyclosporine
- 12.1.7 Others
- 12.2 Vernal Keratoconjunctivitis Market 2018-2034 by Dosage Form
- 12.2.1 Market Overview
- 12.2.2 Ointment
- 12.2.3 Gel
- 12.2.4 Tablets
- 12.2.5 Others
- 12.3 Vernal Keratoconjunctivitis Market 2018-2034 by Distribution Channel
- 12.3.1 Market Overview
- 12.3.2 Hospitals and Clinics
- 12.3.3 Online Pharmacies
- 12.3.4 Retail Pharmacies
- 12.3.5 Others
- 12.4 Vernal Keratoconjunctivitis Market 2018-2034 by Region
- 12.4.1 Market Overview
- 12.4.2 United States
- 12.4.3 EU-4 and the United Kingdom
- 12.4.3.1 Germany
- 12.4.3.2 France
- 12.4.3.3 Italy
- 12.4.3.4 Spain
- 12.4.3.5 United Kingdom
- 12.4.4 Japan
- 12.4.5 India
- 13 United States Vernal Keratoconjunctivitis Market 218-2034
- 13.1 United States Vernal Keratoconjunctivitis Market 2018-2034 by Treatment
- 13.1.1 Market Overview
- 13.1.2 Nonsteroidal Anti-inflammatory Drugs - NSAIDs
- 13.1.3 Mast Cell Stabilizers
- 13.1.4 Antihistamines
- 13.1.5 Topical Corticosteroids
- 13.1.6 Cyclosporine
- 13.1.7 Others
- 13.2 United States Vernal Keratoconjunctivitis Market 2018-2034 by Dosage Form
- 13.2.1 Market Overview
- 13.2.2 Ointment
- 13.2.3 Gel
- 13.2.4 Tablets
- 13.2.5 Others
- 13.3 United States Vernal Keratoconjunctivitis Market 2018-2034 by Distribution Channel
- 13.3.1 Market Overview
- 13.3.2 Hospitals and Clinics
- 13.3.3 Online Pharmacies
- 13.3.4 Retail Pharmacies
- 13.3.5 Others
- 14 EU-4 and United Kingdom Vernal Keratoconjunctivitis Market 218-2034
- 14.1 EU-4 and United Kingdom Vernal Keratoconjunctivitis Market 2018-2034 by Treatment
- 14.1.1 Market Overview
- 14.1.2 Nonsteroidal Anti-inflammatory Drugs - NSAIDs
- 14.1.3 Mast Cell Stabilizers
- 14.1.4 Antihistamines
- 14.1.5 Topical Corticosteroids
- 14.1.6 Cyclosporine
- 14.1.7 Others
- 14.2 EU-4 and United Kingdom Vernal Keratoconjunctivitis Market 2018-2034 by Dosage Form
- 14.2.1 Market Overview
- 14.2.2 Ointment
- 14.2.3 Gel
- 14.2.4 Tablets
- 14.2.5 Others
- 14.3 EU-4 and United Kingdom Vernal Keratoconjunctivitis Market 2018-2034 by Distribution Channel
- 14.3.1 Market Overview
- 14.3.2 Hospitals and Clinics
- 14.3.3 Online Pharmacies
- 14.3.4 Retail Pharmacies
- 14.3.5 Others
- 15 Japan Vernal Keratoconjunctivitis Market 218-2034
- 15.1 Japan Vernal Keratoconjunctivitis Market 2018-2034 by Treatment
- 15.1.1 Market Overview
- 15.1.2 Nonsteroidal Anti-inflammatory Drugs - NSAIDs
- 15.1.3 Mast Cell Stabilizers
- 15.1.4 Antihistamines
- 15.1.5 Topical Corticosteroids
- 15.1.6 Cyclosporine
- 15.1.7 Others
- 15.2 Japan Vernal Keratoconjunctivitis Market 2018-2034 by Dosage Form
- 15.2.1 Market Overview
- 15.2.2 Ointment
- 15.2.3 Gel
- 15.2.4 Tablets
- 15.2.5 Others
- 15.3 Japan Vernal Keratoconjunctivitis Market 2018-2034 by Distribution Channel
- 15.3.1 Market Overview
- 15.3.2 Hospitals and Clinics
- 15.3.3 Online Pharmacies
- 15.3.4 Retail Pharmacies
- 15.3.5 Others
- 16 India Vernal Keratoconjunctivitis Market 218-2034
- 16.1 India Vernal Keratoconjunctivitis Market 2018-2034 by Treatment
- 16.1.1 Market Overview
- 16.1.2 Nonsteroidal Anti-inflammatory Drugs - NSAIDs
- 16.1.3 Mast Cell Stabilizers
- 16.1.4 Antihistamines
- 16.1.5 Topical Corticosteroids
- 16.1.6 Cyclosporine
- 16.1.7 Others
- 16.2 India Vernal Keratoconjunctivitis Market 2018-2034 by Dosage Form
- 16.2.1 Market Overview
- 16.2.2 Ointment
- 16.2.3 Gel
- 16.2.4 Tablets
- 16.2.5 Others
- 16.3 India Vernal Keratoconjunctivitis Market 2018-2034 by Distribution Channel
- 16.3.1 Market Overview
- 16.3.2 Hospitals and Clinics
- 16.3.3 Online Pharmacies
- 16.3.4 Retail Pharmacies
- 16.3.5 Others
- 17 Regulatory Framework
- 17.1 Regulatory Overview
- 17.2 US FDA
- 17.3 EU EMA
- 17.4 Japan PMDA
- 17.5 India CDSCO
- 17.6 Others
- 18 Patent Analysis
- 18.1 Analysis by Type of Patent
- 18.2 Analysis by Publication Year
- 18.3 Analysis by Issuing Authority
- 18.4 Analysis by Patent Age
- 18.5 Analysis by CPC Analysis
- 18.6 Analysis by Patent Valuation
- 19 Clinical Trials Analysis
- 19.1 Analysis by Trial Registration Year
- 19.2 Analysis by Trial Status
- 19.3 Analysis by Trial Phase
- 19.4 Analysis by Therapeutic Area
- 19.5 Analysis by Geography
- 20 Grants Analysis
- 20.1 Analysis by Year
- 20.2 Analysis by Amount Awarded
- 20.3 Analysis by Issuing Authority
- 20.4 Analysis by Grant Application
- 20.5 Analysis by Funding Institute
- 20.6 Analysis by NIH Departments
- 20.7 Analysis by Recipient Organization
- 21 Funding and Investment Analysis
- 21.1 Analysis by Funding Instances
- 21.2 Analysis by Drug Class of Funding
- 21.3 Analysis by Funding Amount
- 21.4 Analysis by Leading Players
- 21.5 Analysis by Leading Investors
- 21.6 Analysis by Geography
- 22 Strategic Initiatives
- 22.1 Analysis by Partnership Instances
- 22.2 Analysis by Drug Class of Partnership
- 22.3 Analysis by Leading Players
- 22.4 Analysis by Geography
- 23 Supplier Landscape
- 23.1 Market Share Analysis, By Region (Top 5 Companies)
- 23.2 Santen Pharmaceutical Co., Ltd.
- 23.2.1 Financial Analysis
- 23.2.2 Product Portfolio
- 23.2.3 Demographic Reach and Achievements
- 23.2.4 Companies News and Developments
- 23.2.5 Certifications
- 23.3 Novartis Pharmaceuticals Corporation
- 23.3.1 Financial Analysis
- 23.3.2 Product Portfolio
- 23.3.3 Demographic Reach and Achievements
- 23.3.4 Companies News and Developments
- 23.3.5 Certifications
- 23.4 Senju Pharmaceutical Co., Ltd.
- 23.4.1 Financial Analysis
- 23.4.2 Product Portfolio
- 23.4.3 Demographic Reach and Achievements
- 23.4.4 Companies News and Developments
- 23.4.5 Certifications
- 23.5 Akari Therapeutics Plc.
- 23.5.1 Financial Analysis
- 23.5.2 Product Portfolio
- 23.5.3 Demographic Reach and Achievements
- 23.5.4 Companies News and Developments
- 23.5.5 Certifications
- 23.6 Allakos Inc.
- 23.6.1 Financial Analysis
- 23.6.2 Product Portfolio
- 23.6.3 Demographic Reach and Achievements
- 23.6.4 Companies News and Developments
- 23.6.5 Certifications
- 23.7 Satellos Bioscience Inc.
- 23.7.1 Financial Analysis
- 23.7.2 Product Portfolio
- 23.7.3 Demographic Reach and Achievements
- 23.7.4 Companies News and Developments
- 23.7.5 Certifications
- 23.8 Viatris Inc.
- 23.8.1 Financial Analysis
- 23.8.2 Product Portfolio
- 23.8.3 Demographic Reach and Achievements
- 23.8.4 Companies News and Developments
- 23.8.5 Certifications
- 23.9 Aldeyra Therapeutics, Inc.
- 23.9.1 Financial Analysis
- 23.9.2 Product Portfolio
- 23.9.3 Demographic Reach and Achievements
- 23.9.4 Companies News and Developments
- 23.9.5 Certifications
- 23.10 Laboratoires Thea S.A.S.
- 23.10.1 Financial Analysis
- 23.10.2 Product Portfolio
- 23.10.3 Demographic Reach and Achievements
- 23.10.4 Companies News and Developments
- 23.10.5 Certifications
- 23.11 Astellas Pharma Inc.
- 23.11.1 Financial Analysis
- 23.11.2 Product Portfolio
- 23.11.3 Demographic Reach and Achievements
- 23.11.4 Companies News and Developments
- 23.11.5 Certifications
- 24 Vernal Keratoconjunctivitis Market - Distribution Model (Additional Insight)
- 24.1 Overview
- 24.2 Potential Distributors
- 24.3 Key Parameters for Distribution Partner Assessment
- 25 Key Opinion Leaders (KOL) Insights (Additional Insight)
- 26 Payment Methods (Additional Insight)
- 26.1 Government Funded
- 26.2 Private Insurance
- 26.3 Out-of-Pocket
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
